INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $124,580 | -38.6% | 11,264 | -23.3% | 0.00% | – |
| Q2 2022 | $203,000 | +9.7% | 14,691 | +29.5% | 0.00% | – |
| Q1 2022 | $185,000 | -56.2% | 11,347 | -33.7% | 0.00% | -100.0% |
| Q4 2020 | $422,000 | +46.5% | 17,104 | +146.1% | 0.00% | 0.0% |
| Q3 2020 | $288,000 | -20.2% | 6,949 | -7.7% | 0.00% | 0.0% |
| Q2 2020 | $361,000 | +8.4% | 7,526 | +178.9% | 0.00% | 0.0% |
| Q4 2019 | $333,000 | +3.4% | 2,698 | -44.3% | 0.00% | 0.0% |
| Q3 2019 | $322,000 | +24.8% | 4,842 | +107.9% | 0.00% | 0.0% |
| Q1 2019 | $258,000 | +13.2% | 2,329 | +2.7% | 0.00% | 0.0% |
| Q4 2018 | $228,000 | -60.4% | 2,268 | -4.9% | 0.00% | -50.0% |
| Q2 2015 | $576,000 | +66.0% | 2,386 | +94.3% | 0.00% | 0.0% |
| Q1 2015 | $347,000 | +57.0% | 1,228 | -13.4% | 0.00% | +100.0% |
| Q4 2014 | $221,000 | – | 1,418 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |